NASDAQ: CTNM
Contineum Therapeutics Inc Stock Ownership - Who owns Contineum Therapeutics?

Insider buying vs selling

Have Contineum Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Daniel S. LorrainChief Scientific Officer2024-11-251,010$16.02
$16.18kSell
Daniel S. LorrainChief Scientific Officer2024-11-1899$17.05
$1.69kSell
Daniel S. LorrainChief Scientific Officer2024-11-186,091$16.37
$99.73kSell

1 of 1

CTNM insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CTNM insiders and whales buy or sell their stock.

CTNM Shareholders

What type of owners hold Contineum Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Johnson Johnson7.06%1,979,173$24.45MInstitution
Johnson Johnson7.06%1,979,173$24.45MInsider
Suvretta Capital Management LLC6.13%1,720,000$21.25MInstitution
Franklin Resources Inc6.06%1,698,825$20.99MInstitution
Fmr LLC3.01%843,150$10.42MInstitution
Sectoral Asset Management Inc2.86%800,787$9.89MInstitution
Vanguard Group Inc2.65%744,001$9.19MInstitution
Perceptive Advisors LLC2.49%699,486$8.64MInstitution
Hhlr Advisors Ltd2.39%669,337$8.27MInstitution
Red Tree Management LLC2.28%638,158$7.88MInstitution

1 of 3

CTNM vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CTNM49.41%9.63%Net Selling
GALT11.63%88.37%Net BuyingNet Buying
DSGN45.90%54.10%Net SellingNet Selling
RCKT50.37%49.63%Net SellingNet Selling
BNTC88.61%8.18%Net Buying

Contineum Therapeutics Stock Ownership FAQ

Who owns Contineum Therapeutics?

Contineum Therapeutics (NASDAQ: CTNM) is owned by 49.41% institutional shareholders, 9.63% Contineum Therapeutics insiders, and 40.96% retail investors. Johnson Johnson is the largest individual Contineum Therapeutics shareholder, owning 1.98M shares representing 7.06% of the company. Johnson Johnson's Contineum Therapeutics shares are currently valued at $24.45M.

If you're new to stock investing, here's how to buy Contineum Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.